Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study

This presentation details the long-term efficacy and safety outcomes from a Phase 3 study comparing lorlatinib to crizotinib for patients with advanced non-small cell lung cancer. It outlines how lorlatinib provides prolonged systemic and intracranial disease control, resisting common mutations while maintaining a consistent safety profile over several years. Additionally, the text incorporates genetic analysis to distinguish baseline biomarkers between early progressors and long-term treatment responders.